Objectives: We sought to evaluate the effectiveness and safety of rivaroxaban vs apixaban in non-valvular atrial fibrillation (NVAF) patients with end-stage renal disease (ESRD) and/or receiving dialysis in routine practice.
Methods: Using US MarketScan claims data from January 1, 2014, to December 31, 2017, we identified new-users of rivaroxaban or apixaban during 2015 with at least 12 months of insurance coverage prior to oral anticoagulant (OAC) initiation. Differences in baseline covariates between cohorts were adjusted using inverse probability-of-treatment weighting based on propensity scores. Patients were followed for stroke or systemic embolism (SSE) or major bleeding hospitalizations. Cox proportion hazards regression was used to compare rivaroxaban and apixaban. Analyses stratified by age, sex, CHA2DS2-VASc score, prior stroke, prior bleed, diabetes, and reduced OAC dose were performed.
Results: We identified 787 rivaroxaban and 1836 apixaban users. Median (25, 75% range) age = 70 (61, 79), CHA2DS2-VASc score = 3 (2, 4), and follow-up = 0.87 (0.38, 1.56) years. No differences in the risks of SSE (HR = 1.18, 95% CI = 0.53-2.63), ischemic stroke (HR = 1.12, 95%CI = 0.45-2.76), or major bleeding (HR = 1.00, 95% CI = 0.63-1.58) were observed. No significant interactions were observed upon subgroup analysis.
Conclusion: In NVAF patients with ESRD and/or receiving dialysis, rivaroxaban and apixaban were associated with similar risks of SSE and major bleeding.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ejh.13383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation.
J Thromb Haemost
March 2025
MAHSC Professor, University of Manchester, Oxford Road, Manchester, United Kingdom.
Monitoring unfractionated heparin (UFH) to ensure effective anticoagulation may be performed using anti-factor Xa activity (anti-Xa) instead of the activated partial thromboplastin time. However, in patients who have been treated with oral factor Xa (FXa) inhibitors (apixaban, rivaroxaban, and edoxaban) while switching to UFH therapy, there is a risk that these oral anti-FXa drugs could interfere with UFH calibrated anti-Xa monitoring. This may lead to inappropriate anticoagulation management.
View Article and Find Full Text PDFExpedited Hip Fracture Surgery in Patients on Direct Oral Anticoagulants Does Not Increase Perioperative Blood Loss.
J Orthop Trauma
March 2025
Department of Orthopaedic Surgery, Cedars Sinai Medical Center, Los Angeles, CA.
Objectives: To compare blood loss and transfusion rates in geriatric hip fracture patients on direct oral anticoagulants undergoing surgery ≤ 24 hours from admission (Expedited group) versus 24-72 hours from admission (Delayed group).
Methods: Design: Retrospective cohort study.
Setting: Level I Trauma Center.
Triple antithrombotic therapy or 'triple therapy' describes the combination of 3 oral antithrombotic medications - an anticoagulant drug (warfarin, apixaban, rivaroxaban or dabigatran) and 2 antiplatelet drugs (usually aspirin plus clopidogrel). Most commonly, triple therapy is indicated for patients who require dual antiplatelet therapy following coronary stent insertion for acute coronary syndrome and long-term anticoagulation for atrial fibrillation. Current evidence supports shorter durations of triple therapy to mitigate bleeding risks without compromising ischaemic protection.
View Article and Find Full Text PDFVirtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban.
Br J Clin Pharmacol
March 2025
Division of General Internal Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland.
Aims: In a large cohort of hospitalized patients, previously validated physiologically based pharmacokinetic (PBPK)-based models for apixaban and rivaroxaban are being assessed for their performance in predicting individual pharmacokinetics, aiming to identify patients at high risk of under- or overdosing based on demographic, physiological and CYP-related phenotypic characteristics.
Methods: Clinical data were collected from hospitalized patients treated with apixaban (n = 100) or rivaroxaban (n = 100) at the Geneva University Hospitals (HUG). These patients were recruited in the OptimAT trial (NCT03477331).
Readily available and rapid turn-around, bedside assays to measure the effect of the direct oral anticoagulants (DOACs) are not available. This study evaluates a point-of-care (PoC) coagulometer to assess the anticoagulant effects of the DOACs and low molecular weight heparin. Studies were done in fresh spiked blood from healthy volunteers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!